Myocardial protection in paediatric cardiac surgery: building an evidence-based strategy.

Cardioplegia is fundamental to the surgical repair of congenital heart defects by protecting the heart against ischaemia/reperfusion injury, characterised by low cardiac output and troponin release in the early postoperative period. The immature myocardium exhibits structural, physiological and metabolic differences from the adult heart, with a greater sensitivity to calcium overload-mediated injury during reperfusion. Del Nido cardioplegia was designed specifically to protect the immature heart, is widely used in North America and may provide better myocardial protection in children; however, it has not been commercially available in the UK, where most centres use St Thomas' blood cardioplegia. There are no phase 3 clinical trials in children to support one solution over another and this lack of evidence, combined with variations in practice, suggests the presence of clinical equipoise. The best cardioplegia solution for use in children, and the impact of age and other clinical factors remain unknown. In this Hunterian lecture, I propose an evidence-based strategy to improve myocardial protection during cardiac surgery in children through: (1) conducting multicentre clinical trials of established techniques; (2) improving our knowledge of ischaemia/reperfusion injury in the setting of cardioplegic arrest; (3) applying this to drive innovation, moving beyond current cardioplegia solutions; (4) empowering personalised medicine, through combining clinical and genomic data, including ethnic diversity; and (5) understanding the impact of cardioplegic arrest on the late outcomes that matter to patients and their families.

Non-invasive cardiac output monitoring with electrical velocimetry after cardiac surgery in infants.

INTRODUCTION: Low cardiac output following cardiac surgery is a major determinant of outcome that may be improved by early detection, yet there are no widely accepted methods for its measurement in young children. We evaluated the feasibility of the routine use of electrical velocimetry, a non-invasive technique providing continuous measurement of cardiac output, in infants in the early postoperative period. METHODS: With ethical approval and parental consent, infants undergoing cardiac surgery were recruited. The ICON electrical velocimetry monitor was attached on admission to the intensive care unit (ICU) and remained for up to 24h. RESULTS: A total of 15 infants were recruited, median age 3 months (interquartile range (IQR) 0.5-7.5) and weight 4.8kg (IQR 3.9-7.1), undergoing various operations. Cardiac index had a weak correlation with arterial lactate (r=-0.24, p=0.02) and no correlation with blood pressure, central venous pressure or arteriovenous oxygen difference. Data were recorded for a median of 19h (range 5-24), with lead detachment or movement artefact the most common causes of data loss. There was marked minute-to-minute variability, with 25% of consecutive measurements having >5% variability. CONCLUSION: Cardiac index measured by electrical velocimetry in infants in the early postoperative period is impaired by frequent data loss and marked intrapatient variability. Our feasibility study suggests that it is unsuitable for use as a routine monitoring tool in the setting of postsurgical ICU care.

The impact of genetic outreach education and support to primary care on practitioner's confidence and competence in dealing with familial cancers.

AIMS: To determine the level of competence and confidence in general practice in relation to the management of familial cancers and to determine the impact of providing genetic educational outreach on confidence and competence. METHODS: Confidence and competence in dealing with familial cancers was measured using a postal questionnaire sent to all general practitioners and practice nurses in 4 geographical areas in central England. In 2 areas, genetic educational outreach was provided to 10 randomly selected practices and a matched analysis of questionnaire responses before and after intervention was done to determine the impact of the intervention. RESULTS: Respondents were more confident in dealing with patient queries around familial breast cancer risk than those around bowel cancer. This was inconsistent with the ability to correctly assign familial risk, with 48% incorrectly assigning a high-risk categorisation to a low-risk breast cancer scenario. Respondents who had taken part in the intervention reported more confidence in dealing with issues related to the management of patient queries around bowel cancer. Following intervention, participants were more likely to report feeling confident in knowing the relevant family history to collect (72.4% of respondents from participating practices compared to 56.1% from non-participating practices; OR 2.39, p = 0.02, 95% CI 1.14-5.00) and in making a basic assessment of risk (72.4% compared to 38.9%; OR 3.65, p = 0.01, 95% CI 1.38-9.61). CONCLUSIONS: Providing genetic educational outreach has a positive impact upon how confident primary care staff feel in dealing with patient queries over familial cancers, particularly in relation to bowel cancer. Further research is needed to explore the impact of providing this service on other relevant outcomes such as appropriateness of referrals to genetic services.

Genetics support to primary care practitioners - a demonstration project.

Primary care practitioners need to be supported by specialist genetics services to enable them to cope effectively with the expanding relevance of genetics to their patients. Genetic counselors could be effective in such a role. This exploratory project set out to improve the Primary-Tertiary interface through piloting such a service to general practice for 1 year. Tailored genetic educational outreach was delivered by a genetic counselor to ten randomly selected general practices in central England for 12 months. A range of services were provided to the practices these included facilitated genetic update sessions, a responsive advice service and referral guidelines. The service was evaluated through pre and post intervention questionnaires and via seven semi-structured interviews. This article presents a description of the development and delivery of this service and also reports on the experiences of a sample of the participants. Participants reported positive attitudes to the service and said that they had gained knowledge and confidence, as well as recognized limitations and gaps in their current knowledge. The consistent link with a specialist genetics service provided by a genetic counselor had a positive impact during the project and participants have continued to utilize the genetic counselor for advice and support with genetic patient issues since the project was completed. This is the first example of this model of service provision. Further research, utilizing a larger sample and other measures of behavioral change needs to be carried out to assess whether this model should be adopted on a wider basis.

Recurrent noisy pneumothorax mimicking pericarditis.

Sounds related to the cardiac cycle may have an extra-cardiac origin. We report a case of recurrent noisy pneumothorax producing a loud rub, audible at a distance from the patient and initially diagnosed as pericarditis. The sounds and their mechanisms of production in this condition are also discussed.

Cardiac troponin I: evaluation I of a biomarker for the diagnosis of heart disease in the dog.

OBJECTIVES: To assess the value of measuring blood levels of the myocardial protein cardiac troponin I (cTnl) in the diagnosis of congenital and acquired heart disease in the dog and in the evaluation of the severity of heart failure. METHODS: Serum samples obtained from healthy dogs (n = 26) and from dogs diagnosed with a variety of congenital and acquired heart conditions (n = 35) were assayed for cTnl concentration using an automated immunoassay method. Results were also analysed according to the degree of heart failure as assessed using the International Small Animal Cardiac Health Council's scheme. RESULTS: Healthy dogs had very low or undetectable blood cTnl levels, as did dogs with congenital heart disease. However, cTnl levels were significantly elevated in dogs with acquired mitral valve disease, dilated cardiomyopathy and pericardial effusion. Blood cTnl levels also varied with severity of heart failure. CLINICAL SIGNIFICANCE: Measurement of blood cTnl levels may be a useful aid in the diagnosis of dogs with suspected heart disease and in indicating the severity of heart failure.

The prevalence of chronic chest and leg pain following cardiac surgery: a historical cohort study.

Chronic pain after surgery is recognised as an important post-operative complication; recent studies have shown up to 30% of patients reporting persistent pain following mastectomy and inguinal hernia repair. No large-scale studies have investigated the epidemiology of chronic pain at two operative sites following coronary artery bypass grafting (CABG). This paper reports the follow-up of a cohort of 1348 patients who underwent cardiac surgery between 1996 and 2000 at one cardiothoracic unit in northeast Scotland. Chronic pain was defined as pain in the location of surgery, different from that suffered pre-operatively, arising post-operatively and persisting beyond 3 months. The survey questionnaire consisted of the short-form-36 (SF-36), Rose angina questionnaire, McGill pain questionnaire and the University of California and San Francisco (UCSF) pain service questionnaire. Of the 1080 responders, 130 reported chronic chest pain, 100 chronic post-saphenectomy pain and 194 reported pain at both surgical sites. The cumulative prevalence of post-cardiac surgery pain was 39.3% (CI(95) 36.4-42.2%) and mean time of 28 months since surgery (SD 15.3 months). Patients who reported pain at both sites had lower quality of life scores across all eight health domains compared to patients with pain at one site only and those who were pain-free. Prevalence of chronic pain decreased with age, from 55% in those aged under 60 years to 34% in patients over 70 years. Patients with pre-operative angina and those who were overweight or obese (BMI>/=25) at the time of surgery were more likely to report chronic pain. Chronic pain following median sternotomy and saphenous vein harvesting is more common than hitherto reported and that patients undergoing CABG should be warned of this possibility.

Evidence-based guidelines for the use of defibrillation pads.

OBJECTIVE: Defibrillation pads are used routinely at both cardiac arrests and cardioversion procedures. There are currently no evidence-based guidelines on how often pads should be replaced, although it has been suggested that they should be changed as often as every three shocks to maintain optimal performance. Previously, we have shown that on exposure to air, pad mass diminishes over time due to evaporation--an effect likely to lead to poorer conduction between skin and paddle. This prospective study was designed to determine if evaporation is accelerated by the passage of a defibrillation current and to formulate evidence-based guidelines for defibrillation pad replacement. MATERIALS AND METHODS: 3M defibrillation pads (2346N) were collected from acute wards and emergency departments in two hospitals in the UK over a 2 month period. The duration of exposure to air, number and energy of shocks, and type of procedure were recorded. When no longer required, pad masses were determined and the loss of pad mass due to evaporation calculated. RESULTS: 26 pairs of pads were collected from 14 cardiac arrests and 12 cardioversions. The total defibrillation energy used ranged from 150 to 5080 J and evaporative drying time from 4 to 38 min. The rate of evaporation from these pads (86.1 mg x min(-1)) was not significantly different from pads previously studied on volunteers in the absence of a defibrillation current (99.4 mg x min(-1)). Of the defibrillation pads exposed to air for less than 30 min, in only one of 49 pads was the loss of mass due to evaporation consistent with a significant increase in transthoracic impedance (TTI). Correspondingly, of two pads used for more than 30 min, both attained a mass consistent with a significant increase in TTI. CONCLUSIONS: Defibrillation pads can be used for up to 30 min without evaporation causing a clinically significant increase in TTI. The passage of a defibrillation current across pads does not further accelerate water loss.

Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells.

Syndecan-1 is a cell surface proteoglycan that is expressed on human myeloma cells and is thought to act as a co-receptor for certain extracellular matrix proteins and growth factors. The ectodomain of syndecan-1 is thought to be shed from the surface of myeloma cells, although the exact mechanism of release remains unclear. In this study, we used a panel of inhibitors to identify the class of proteinase responsible for shedding the soluble syndecan-1 ectodomain from human myeloma cells. Using enzyme-linked immunosorbent assay, flow cytometry and immunocytochemistry, we demonstrated that myeloma cell lines expressed syndecan-1 on their surface and that this was shed constitutively, but to a varying extent. In addition, phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C, stimulated a marked loss of cell surface syndecan-1 from each of the cell lines and this was associated with a corresponding increase in soluble syndecan-1. Inhibitors of serine and cysteine proteinases, and matrix-type metalloproteinases, did not inhibit constitutive or PMA-stimulated syndecan-1 shedding from JJN3 and RPMI 8226 cells. However, BB-94, a hydroxamate-based, broad-spectrum, metalloproteinase inhibitor, substantially suppressed constitutive and PMA-stimulated syndecan-1 loss from myeloma cells. These data indicate that a non-matrix-type metalloproteinase is responsible for syndecan-1 shedding from the surface of myeloma cells.

How often should defibrillation pads be changed?: the effect of evaporative drying.

OBJECTIVE: In order to minimise transthoracic impedance (TTI) during defibrillation, water-based pads are used to improve conductivity between metal defibrillation paddles and skin. Subjectively, these pads appear to dry very quickly; an effect that may lead to an increase in TTI due to poorer conduction between paddles and skin. This study was carried out to assess the effect of evaporative drying of defibrillation pads on TTI. MATERIALS AND METHODS: TTI was measured at 5-10 min intervals in 20 adult male volunteers across 3M defibrillation pads (2346N) placed in the anterior-apical position. Measurements of TTI were made at 30 kHz using a Bodystat MultiScan 5000 monitor at end-expiration. A third pad was placed on the left precordium and its mass recorded each time a TTI measurement was made. RESULTS: The median age of subjects was 22 years (range 21-52 years) and their median body mass index was 23.1 kg m(-2) (range 18.4-42.8 kg m(-2)). Median room temperature was 23.0 degrees C (range 19.0-24.0 degrees C) and the median humidity was 31.0% (range 28.0-48.0%). 3M defibrillation pads had an initial mean mass of 25.14 g (S.D. +/- 0.41 g). Changes in defibrillation pad mass due to evaporative loss occurred immediately and rapidly, with all measurements being significantly lower than the baseline value. Mean baseline TTI was 63.6 ohms (S.D. +/- 13.7 ohms). After 30 min a statistically significant (P = 0.012) rise of 1.4 ohms (2.2%), was observed corresponding to a 12.6% decrease in pad mass, after which TTI continued to increase in a linear fashion. CONCLUSION: In the absence of a defibrillation current. 3M defibrillation pads can safely be left on the chest wall for at least 25 min in a typical hospital environment before evaporative drying results in a significant increase in transthoracic impedance.